A recent New York Times article highlights Dr. Amy S. Kelley's examination of the Health and Retirement Survey, published in the Annals of Internal Medicine, which found dementia to be far more expensive than the other leading killers—heart disease and cancer. Alzheimer’s care often requires expenses not covered by Medicare, including caregivers who supervise patients and assist them with basic activities. The out-of-pocket cost for a dementia patient averages $61,522, which is more than 80 percent higher than heart disease or cancer.
In many cases, the entire savings of the patient is exhausted, leaving family members responsible for covering extra costs. This puts a strain on a significant portion of the population, and impacts our economy more than any other disease. To fight Alzheimer’s and help these families, GHR has committed more than $17 million over 5 years to scale up important research already underway. The Foundation is targeting funding to improve some of the largest research efforts in the field.
To learn more about how GHR Foundation is supporting innovative new treatments and screenings as we move toward the prevention of Alzheimer’s disease, contact us.